Biofourmis Pushes To Make Remote Medical Tools The New Normal

Singapore- and Boston-based Biofourmis uses Artificial Intelligence (AI) technology to develop “personally predictive” care that can help treat patients with chronic conditions no matter where they are. In a time where the ability to monitor one’s health consistently and conveniently has become increasingly important, Biofourmis is using wearable tech to help address this need.

Their FDA-approved wearable biosensor analyzes dozens of signals from each patient and compares the data to millions of other patients. The technology is then able to recognize impactful patterns that can help providers recognize the signs of negative health events before they occur.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

Biofourmis recently raised $100 million in a Series C funding round. SoftBank Vision Fund 2 led the round, and returning investors Openspace Ventures, MassMutual Ventures, Sequoia Capital, and EDBI also participated. This round came a little over a year after the company’s Series B round, which secured $35 million. Biofourmis has raised a total of $145 million to date.

Biofourmis and pharma companies work together to find ways of improving existing treatments. Drug efficacy can be measured by analyzing data collected from the wearable device. Metrics like heart rate, blood pressure, and oxygen saturation are also tracked and saved. A smartphone app makes it easy for users to keep an eye on their stats, while the data is also transferred to an electronic health record system that can alert doctors the minute anything is registered as a red flag.

The company plans to use the recent investment to bring some new digital therapeutic tools and platforms to the market, as well as expand their footprint throughout Asia, including in China and Japan. Biofourmis is also restructuring its business so its operations fall under one of two categories - Biofourmis Therapeutics and Biofourmis Health. The therapeutics division will focus on creating software to increase the efficacy of pharmaceutical treatments, partnering with companies like AstraZeneca. Biofourmis Health will focus on developing the “home health” devices and software that allow its users to keep a watchful eye on their health as they shift from acute care back into their regular routines.

The company hopes their platforms will enable patients with respiratory illnesses, heart disease, and cancer lead more normal lives at home while being able to maintain a close connection with their network of providers.